The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML).
Masamichi Mori
Employment or Leadership Position - Masamichi Mori
Naoki Kaneko
Employment or Leadership Position - Astellas Pharma
Yoko Ueno
Employment or Leadership Position - Astellas Pharma
Ruriko Tanaka
Employment or Leadership Position - Astellas Pharma
Kathy Cho
Employment or Leadership Position - Astellas Research Institute of America
Rika Saito
Employment or Leadership Position - Astellas Pharma
Yutaka Kondoh
Employment or Leadership Position - Astellas Pharma
Itsuro Shimada
Employment or Leadership Position - Astellas Pharma
Sadao Kuromitsu
Employment or Leadership Position - Astellas Pharma